📰 GeneralTechCrunchWednesday, September 23, 2026 at 7:31 PM UTC1h ago

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s

Read full article at TechCrunch →

Originally published by TechCrunch. Summary and curation by DutyStation News.

← Back to News

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

📰 Related Stories

VC firm Bessemer now has another $5.75B to invest in (what else?) AI

Microsoft launches 12-inch Surface Pro with Snapdragon X2 Plus & 5G, 13-inch Surface Laptop too

Microsoft refreshes its smaller Surface Pro and Laptop with Qualcomm’s X2 Plus

Microsoft’s new Surface Mouse has haptic feedback and a customizable action button

XPRIZE Wildfire winners spotted fires within 10 min—but couldn’t stop them

Google Maps update shows traffic lights and stop signs at your next turn on Android Auto, more